AbbVie and Disco strike deal worth up to $2.54B for solid tumor targets
AbbVie is partnering with Disco Pharmaceuticals, a preclinical cancer biotech, to build out its antibody-drug conjugate and T cell engager programs. The Cologne, Germany-headquartered biotech will receive $40 million upfront and up to $2.5 billion ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.